1. Moore WC, Kornmann O, Humbert M, et al. Affairs portal to a separate website maintained by 10. . GSK Director, US Medical Affairs, Adult Immunization and Health Equity Durham, NC 30d+ $71K-$112K Per Year (Glassdoor est.) Visit Lee LA, Boulet LP, Fowler A, et al. (Poster No. Information Database, Vaccine Temperature POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. Ferguson GT, Brown N, Compton C, et al. 3. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients? Goodall E, Wood R, Numbere B, et al. Meta-analysis From Two Phase 3 Trials. POSTER: Demographics and survival outcomes in patients (pts) with advanced or recurrent (A/R) endometrial cancer (EC) in the English real-world (RW) setting, 1.POSTER: Real world data of Niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group (Presentation Is Not Available Due to Copyright), 1. P824; Abstract A4313]. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility. P1481. 2017;276(1):80-96. 22 Gsk Medical Affairs jobs in London, England, United Kingdom (2 new) Today's top 22 Gsk Medical Affairs jobs in London, England, United Kingdom. 340), 1. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. [Poster No. 2. 2. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. Poster No. 4. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. Singh AK, et al. Dyck L, Mills KHG. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. 3. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone? [Poster No. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. GSK is an Equal Opportunity/Affirmative Action Employer. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Achieving SLE Disease Control or LLDAS and Lower Organ Damage Rates, 2. 1. #Vaccine Twitter Influencers: Is it Just About Reach and Followers? Search jobs Life at GSK Careers . Sign In. Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD? and/or LAGE-1a?positive cancers. ORAL PRESENTATION: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer, 1. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 ? Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. This site is intended for US healthcare professionals only. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET, 3. Coyne, D et al. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. This information does not take the place of talking with your doctor. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. Lee J, Pollard S, Liu M, et al. POSTER: Marijam A, et al. Pitrez P, Bruselle G, Yorganc?o?lu A, et al. Mar 2022 - Present1 year 2 months. 2. PD-L1 is expressed by many tumor types and is linked to poor clinical outcomes in a variety of cancers. 3. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. Causes of Death in Patients with Anemia of ?Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial. P1512. Plain Language Summary [HCP USE ONLY]: The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-Analysis, 15. Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and TSR-033 in advanced solid tumors, including melanoma, NSCLC, and colorectal cancer. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial? Poster No. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. [Poster No. When expanded it provides a list of search options that will switch the search inputs to match the current selection. Nature. This effort supports employees by enhancing their strengths and addressing any development gaps through individual and group coaching and sponsorship. Immunol Rev. A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in subjects with non-Hodgkin?s lymphoma (NHL), 3. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. Bogart M, Bengtson L, Rothnie K, et al. POSTER: Open-Label Phase 2, Randomized Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination Deficient Stage III/IV Ovarian Cancer: Trial in Progress, 2. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. POSTER: Real-World Trends of PARPi Maintenance Treatment Uptake and Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) in the US, 8. Poster No. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. 347). 14. pour nous faire part du problme. Note: The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. Gsk Medical Affairs Jobs - 2022 | Indeed.com Start of main content What Date posted Posted By Remote Salary estimate Job type Education level Industry Location Company Post your resume and find your next job on Indeed! Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology Examples: How Can the Patient Voice Make an Impact? 6. Colleagues discuss issues that matter and explore different perspectives. London, ENG. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? GSK Medical Director Jobs | Glassdoor Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Communication with Patients/Parents on MenB Vaccination for Older Adolescents and Young Adults. 3888792. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. 3. 7. The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. Rothnie KJ, Bancroft T, Bogart M, et al. P1483. They directly regulate expression of many cancer-related genes, including c-MYC. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448) Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. 13. Gsk Medical Affairs Jobs in United States, Director of Medical and Clinical Affairs for Flu/COVID-19 Vaccines, Director, US Medical Affairs, Scientific Affairs and Public Health, Director, Vaccines Scientific Communications, ViiV (GSK) Global Medical Affairs Director, Field Based Medical Science Liaison- IL/MI, Vaccine Development Leader (VDL), MAPS Vaccine, Global Regulatory Affairs Manager, Labelling, Director, Independent Medical Education (IME) & Grants, US Medical Affairs Scientific Director, Specialty Pipeline, ViiV (GSK) Director, Community Medical Liaison, Community Engagement Specialist HIV Prevention, Global Medical Affairs Director - Neurosciences. Gsk Medical Jobs in London | Indeed.com Upload your CV and easily apply to jobs from any device! Nat Med. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1?specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial? Liu M, Bagnasco D, Matucci A, et al. 1. Quick Links Grants Compassionate Use Investigator Sponsored Studies GSK study Register (Clinical Trial Data and Trial Recruitment) Oncohematology ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. The winners found large companies with a big Hispanic workforce and created solutions including an employer caregiver toolkit and caretaker programs. Glaxosmithkline Medical Director Jobs March, 2023 (Hiring Now!) - Zippia Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States ? Lan Y, Zhang D, Xu C, et al. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. (Poster No. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. 2015;23:82-91. Singh AK, et al. CD96 is an immune checkpoint protein expressed on T cells and natural killer (NK) cells in multiple tumor types. Poster No. It inspires every one of us to do our best work. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta?) Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. Schwarz TF et al. POSTER: Trennery CL, Martin S, Kosa K, et al. GSK. 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. Silver J, Bogart M, Molfino N, et al. Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France?? POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. www.fda.gov/medwatch. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. Insights From Allergy Practice. Bogart M, Chastek B, White J, et al. Trade marks are owned by or licensed to the GSK group of companies. P713; Abstract A1828], 10. Our market sites can be reached by visiting our location selector. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. 336), 1. signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. Mularski RA, Drummond MB, Jain R, et al. Cho S-F, Anderson KC, Tai Y-T. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448). NY-ESO-1 and LAGE-1a are highly homologous immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. Click here to learn more: gsk.to/3zRZBXY, Are you familiar with the signs and symptoms of #myelofibrosis? A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. NY-ESO-1?specific TCR?engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. GSK Medical Director, Global Medical Affairs - Rheumatology Collegeville, PA 11d $133K-$225K Per Year (Glassdoor est.) para nos informar sobre o problema. , Have you heard of #myelofibrosis, a rare form of blood cancer? 1. We also share information about your use of our site with our advertising, social media and analytics partners. To report suspected adverse reactions, please call us at A Nationwide Multicentric Study, 4. You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. Singh AK, et al. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (2017?2020), 1. [Poster No. P474; Abstract A3997]. 2. 9. P1454. Verhamme K, de Ridder M, Webb D, et al. 1467. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. 4. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents ? Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. This site is intended for US Patients or Caregivers. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. POSTER: Healthcare Costs in Patients With Newly Diagnosed Advanced Ovarian Cancer Receiving Maintenance Treatment With Niraparib Monotherapy Or Active Surveillance In The United States, 2.